Trial Profile
Phase I study of UTTR1147A (IL-22Fc), a potential therapy for epithelial injury in healthy volunteers.
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 22 Jul 2018
Price :
$35
*
At a glance
- Drugs Efmarodocokin alfa (Primary) ; Efmarodocokin alfa (Primary)
- Indications Diabetic foot ulcer; Ulcerative colitis
- Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
- 22 Jul 2018 New trial record
- 28 Jun 2018 Results published in the Clinical Pharmacology and Therapeutics